The silent progression of colorectal cancer from polyps to malignancy

Science · Published 24 October 2026 Swipe more like this →

In short: Colorectal cancer often begins as a small growth called a polyp inside the colon or rectum. Because these early stages frequently present no symptoms, timely screening is critical for prevention. Understanding the genetic pathways and lifestyle factors involved can turn healthcare education into a collaborative tool for survival.

Colorectal cancer (CRC) is currently the third most common cancer globally, accounting for approximately 10% of all cancer cases. In 2022 alone, an estimated 1.9 million new cases were reported worldwide, resulting in more than 900,000 deaths. While it predominantly affects individuals aged 50 and above, there is a concerning rising burden among adults aged 30–50 in certain settings. The disease is characterized by its ability to cause severe illness and premature death, particularly when detected at advanced stages. Incidence rates were highest in Europe and Australia or New Zealand. Mortality was most prevalent in Eastern Europe. In several high-income nations, these figures have dropped due to better early detection.

The pathophysiology of CRC involves complex genetic mutations targeting oncogenes, tumor suppressor genes, and DNA repair mechanisms. These can be classified as sporadic (70%), familial (25%), or inherited (5%). Key disease pathways involve CIMP, MSI, and CIN. Specific mutations in genes like c-MYC, KRAS, and BRAF serve as predictive markers for patient outcomes. Alterations in non-coding RNAs also contribute to the carcinogenesis process.

Furthermore, the gut microbiota plays a significant role; dysbiosis—an imbalance in gut bacteria such as Fusobacterium spp. and Bacteroides fragilis—can induce carcinogenesis through chronic inflammation. Prevention focuses on both lifestyle modifications and clinical intervention. High intake of processed meats, low fruit and vegetable consumption, obesity, smoking, and alcohol use are primary risk factors. Conversely, finding and removing polyps is a key preventive strategy. Therapy usually employs a multi-method strategy, commencing with surgery then using chemotherapy alongside proteins or monoclonal antibodies directed at EGFR and VEGF. Emerging research into ncRNAs and specific gene panels aims to refine prognosis and treatment selection. Clinical trials are currently exploring alternatives like agarose tumor macrobeads or gold-based drugs. These studies aim to improve efficacy while minimizing side effects.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

• The decade-long transition from a harmless polyp to colon cancer
• Can we stop colon cancer before it even begins?
• Half of colorectal cancers hide until screening finds them
• Why bowel cancer is one of our most preventable threats
• Why adding more paths actually makes a circuit easier to travel
• Understanding Community Acquired Pneumonia: A Clinical Overview
• Why quitting nicotine cold turkey rarely works and what science suggests instead
• Uncovering the structural foundations of commutative algebra
• Five scientific theories that were once accepted but later proven entirely wrong
• Why understanding a balance sheet is a superpower for every career
• The fundamental divide between modern behavioral science and deep psychology
• How mathematicians use 'simpler' math to solve complex problems

More in Science · Latest · A–Z · All topics